A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.

Mol Psychiatry 2000 Jul;5(4):410-7

Neurogenetics Section, Clarke Division, Centre for Addiction and Mental Health (CAMH), University of Toronto, Toronto, ON, Canada.

Tardive dyskinesia (TD) is a common and potentially irreversible side effect associated with long-term treatment with typical antipsychotics. Approximately, 80% or more of patients with schizophrenia are smokers. Smoking is a potent inducer of the CYP1A2 enzyme, and is known to cause a significant decrease in plasma concentrations of some antipsychotics. Therefore, person-to-person differences in the extent of CYP1A2 induction by smoking may contribute to risk for the development of TD. Recently, a (C-->A) genetic polymorphism in the first intron of the CYP1A2 gene was found to be associated with variation in CYP1A2 inducibility in healthy volunteer smokers. The aim of this study was to test the clinical importance of the (C-->A) polymorphism in CYP1A2 in relation to TD severity. A total of 85 patients with schizophrenia were assessed for TD severity using the Abnormal Involuntary Movement Scale (AIMS), and were subsequently genotyped for the (C-->A) polymorphism in CYP1A2. The mean AIMS score in patients with the (C/C) genotype (associated with reduced CYP1A2 inducibility) was 2.7- and 3.4-fold greater than in those with the (A/C) or (A/A) genotype, respectively (F[2,82] = 7.4, P = 0.0007). Further, a subanalysis in the 44 known smokers in our sample, revealed a more pronounced effect. The means AIMS score in smokers was 5.4- and 4. 7-fold greater in (C/C) homozygotes when compared to heterozygotes and (A/A) homozygotes, respectively (F[2,41] = 3.7, P = 0.008). These data suggest that the (C-->A) genetic polymorphism in the CYP1A2 gene may serve as a genetic risk factor for the development of TD in patients with schizophrenia. Further studies in independent samples are warranted to evaluate the applicability of our findings to the general patient population receiving antipsychotic medications.

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.mp.4000736DOI Listing
July 2000
71 Reads

Publication Analysis

Top Keywords

cyp1a2 gene
12
polymorphism cyp1a2
12
patients schizophrenia
12
cyp1a2
9
c-->a genetic
8
cyp1a2 inducibility
8
c-->a polymorphism
8
tardive dyskinesia
8
aims score
8
genetic polymorphism
8
subsequently genotyped
4
aims subsequently
4
c/c genotype
4
score patients
4
genotyped c-->a
4
cyp1a2 aims
4
patients c/c
4
reduced cyp1a2
4
34-fold greater
4
greater a/c
4

References

(Supplied by CrossRef)

JM Kane et al.
Arch Gen Psychiatry 1982

MH Chakos et al.
Arch Gen Psychiatry 1996

J Bergen et al.
Biol Psychiatry 1992

CC Peck et al.
Clin Pharmacol Ther 1992

M Rowland et al.
1995

V Ozdemir et al.
CNS Spectrums 1999

P Weinhold et al.
J Clin Psychiatry 1981

R Yassa et al.
Am J Psychiatry 1981

JL Waddington et al.
Br J Psychiatry 1988

E O'Callaghan et al.
Br J Psychiatry 1990

H Rosengarten et al.
Pharmacol Biochem Behav 1994

Similar Publications